eFFECTOR Therapeutics, Inc.’s Post

Join Rahul Chaturvedi, CEO of Clora, as he chats with Ken Keller, President and CEO of Daiichi Sankyo US, on a new episode of the Biotech2050 podcast. Ken shares insights into Daiichi’s strategic pivot to oncology, their industry-leading breakthroughs in antibody-drug conjugates (ADCs), and the success of their HER2-targeted therapies. He also discusses the power of strategic partnerships, building a passionate, impact-driven team, and his visionary perspective on the future of cancer treatments. Listen now using the link below. #Clora #podcast #biotech #oncology #leadership #cancertreatment #adcs #antibodies #HER2

Excited to share the latest Biotech2050 podcast episode with Ken Keller, President and CEO of Daiichi Sankyo US. We explored the evolution of the antibody drug conjugate space and discussed Daiichi Sankyo’s strategic shift from cardiology to oncology. Ken shared his perspective on the critical role of partnerships in driving innovation and progress in today's landscape. We also delved into how operating within a diverse, cross-cultural framework enhances organizational success. Listen now using the link below and join the conversation! #Biotech2050 #podcast #biotech #oncology #innovation #cancertreatment #adcs #antibodies #HER2

In these two podcast episodes, GI oncologists use clinical cases of gastric and gastroesophageal (GE) cancer to demonstrate the application of treatment sequences, biomarker testing, and practice-changing data. In Episode 1, Dr. Samuel Klempner Dr. Elizabeth Smyth focus on a patient with non-metastatic cancer, while Episode 2 looks at a metastatic case, covering the latest developments in the field. Listen to both podcast episodes: https://lnkd.in/eR3XNAN4 Or listen on Spotify, Apple, or Google Podcasts. #MedEd #FreeMedEd #MedicalEducation #Oncology

Have you listened to the latest "BioCentury This Week" podcast? ✅ Topics (1) Why did Europe's CHMP decision on #Leqembi from Eisai Co., Ltd. & Biogen differ from FDA's decision? (2) How will the recent FDA ODAC meeting impact perioperative cancer clinical trials for checkpoint inhibitors? (3) Will the U.S. Pediatric Review Voucher system be renewed before sunset? (4) Plus, the latest on #Biosecure, including new inquiries into pharma clinical trials in China. ✅ Listen 🎧 Apple: https://lnkd.in/d-4Y2FE7 🎧 Spotify: https://lnkd.in/dGKKjD4h 🎧 YouTube: https://lnkd.in/dudjvjnr It's a great discussion from my BioCentury Inc colleagues Simone Fishburn, Selina Koch, PhD, Steve Usdin and Lauren Martz. If you like the podcast, please make sure to leave a review to help others find it! #biotechpodcast #biopharma #drugdevelopment

In the In Conversation With series, a part of the free Drug Discovery World podcast, I speak with members of the drug discovery industry about their work and how it helps turn science into business.     In this episode, I spoke with Steve Worland, CEO of eFFECTOR Therapeutics, Inc.. eFFECTOR is a company targeting three distinct targets central to the eIF4F translation initiation complex: MNK, eIF4A and eIF4E. Each of these targets regulates distinct sets of genes in cancer and immune cells. Listen now and comment below who you think I should speak with next!

🦠 𝗪𝗶𝘁𝗻𝗲𝘀𝘀 𝗮 𝗰𝗮𝗻𝗰𝗲𝗿 𝗰𝗲𝗹𝗹 𝘂𝗻𝗱𝗲𝗿𝗴𝗼𝗶𝗻𝗴 𝗮𝗽𝗼𝗽𝘁𝗼𝘀𝗶𝘀!🔬 In real-time, we can observe morphological changes such as blebbing, cell shrinkage, and chromatin condensation - a hallmark of apoptosis in these T685A human melanoma cancer cells. See how Nanolive's analysis software can identify apoptosis, completely label-free: https://bit.ly/42GmAT6 #biotechnology #sciencecommunication #medtech #innovation #cellimaging #research #technology #celltherapy #pharmaceuticals #biologics #nanolive #cancer #oncology

🔍 Get a clear view of the regulatory landscape and make data-driven decisions. Visit our site for a free trial and demo to learn more → https://lnkd.in/dqzJEea4 #oncology #biotech #biotechnology #regulatoryaffairs #pharma #drugdevelopment #oncologytrials #oncologyresearch #cancer #oncology #regulatoryintelligence #regulatoryprecedent

Heidelberg Pharma AG, first in the world to develop amanitin for cancer therapy, is one of the seven innovative companies listed in the Clarivate Companies to Watch report this year. Heidelberg Pharma AG uses its proprietary ADC payload (ATAC® technology) to develop ADCs called ATACs that have amanitin-based compounds as the payload.     Why is Heidelberg Pharma AG a company to watch?  Download the report to discover innovations transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest, here: https://lnkd.in/eCSaAWtu #oncology #cancertreatement #biotech #pharma #companiestowatch 

The pace of innovation in oncology is in constant flux. From the expansion of CAR-Ts, to growth in precision medicine and the identification of new biomarkers—all of these changes demand new analytics strategies. ZS’s Jeevarasan Elanchelvan, Christina Corridon and Deepika Sinha highlight some of the biggest opportunities for pharma to grow their analytics capabilities to meet today’s challenges in the oncology landscape. #oncology #analytics

The pace of innovation in oncology is in constant flux. From the expansion of CAR-Ts, to growth in precision medicine and the identification of new biomarkers—all of these changes demand new analytics strategies. ZS’s Jeevarasan Elanchelvan, Christina Corridon and Deepika Sinha highlight some of the biggest opportunities for pharma to grow their analytics capabilities to meet today’s challenges in the oncology landscape. #oncology #analytics